This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
Browsing: Disease Area > Lung
Researchers have demonstrated for the first time, in mice, that carbon nanotubes may pose a similar carcinogenic effect as asbestos.
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Researchers have discovered that lung cancer cells are able to utilize lactate as an energy source to facilitate growing. This finding challenges the previous understanding of cancer metabolism and may have implications for future cancer research.
What is the potential clinical significance of the results of the FLAURA trial presented at ESMO? Find out in our exclusive interview.
NICE has announced that the immunotherapy nivolumab will now be made available on the Cancer Drugs Fund for treating locally advanced or metastatic squamous and non-squamous non-small-cell lung cancers after prior chemotherapy.
Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).